This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by L'Allier, P. L. Articles by Tardif, J.-C. Search for Related Content PubMed PubMed Citation Articles by L'Allier, P. L. Articles by Tardif, J.-C.

Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation

Philippe L. L'Allier, MD^*, Anique Ducharme, MD^*, Pierre-Frédéric Keller, MD^*, Holly Yu, MSPH, Marie-Claude Guertin, PhD^* and Jean-Claude Tardif, MD, FACC^*,*

^* Research Center, Montreal Heart Institute, Montreal, Quebec, Canada
Institute for Effectiveness Research, Bridgewater, New Jersey, USA

View larger version (19K): [in a new window]   Figure 1 Kaplan-Meier curves for time to first occurrence of atrial fibrillation (AF). ACEI = angiotensin-converting enzyme inhibitor; CCB = calcium-channel blocker.